Prospective Grant of Exclusive License: Use of Methanocarba Analogues of Purine and Pyrimidine Nucleosides and Nucleotides to Treat or Prevent Cardiac Diseases in Humans, 80955-80956 [2011-33131]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 248 / Tuesday, December 27, 2011 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: John Bishop, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5182,
MSC 7844, Bethesda, MD 20892, (301) 408–
9664, bishopj@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: December 20, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–33135 Filed 12–23–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
sroberts on DSK5SPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the public
in accordance with the provisions set
forth in sections 552b(c)(4) and
552b(c)(6), Title 5 U.S.C., as amended.
The grant applications and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel, Biofilm P01 Review.
Date: January 11, 2012.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6700B
Rockledge Drive, Bethesda, MD 20817,
(Telephone Conference Call).
Contact Person: Tracy A. Shahan, Ph.D.,
MBA, Scientific Review Officer, Scientific
Review Program, NIAID/NIH/DHHS, 6700B
Rockledge Drive, MSC 7616, Bethesda, MD
20892–7616, (301) 451–2606,
tshahan@niaid.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
VerDate Mar<15>2010
22:00 Dec 23, 2011
Jkt 226001
Dated: December 20, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–33134 Filed 12–23–11; 8:45 am]
BILLING CODE 4140–01–P
80955
and Hematology Research, National Institutes
of Health, HHS)
Dated: December 20, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–33132 Filed 12–23–11; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Vitamin D and
Diabetes.
Date: January 25, 2012.
Time: 2 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: D.G. Patel, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes Of Health,
Room 756, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, Comparative
Effectiveness Research.
Date: January 26, 2012.
Time: 7:30 a.m. to 8 a.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda Marriott Suites, 6711
Democracy Boulevard, Bethesda, MD 20817.
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes Of Health,
Room 753, 6707 Democracy Boulevard,
Bethesda, MD 20892–2542, (301) 594–8898,
barnardm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
Prospective Grant of Exclusive
License: Use of Methanocarba
Analogues of Purine and Pyrimidine
Nucleosides and Nucleotides to Treat
or Prevent Cardiac Diseases in
Humans
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services (HHS), is
contemplating the grant of a worldwide
exclusive evaluation option license, to
practice the inventions embodied in
U.S. Provisional Patent Application No.
60/176,373, filed January 14, 2000 and
currently abandoned [HHS Ref. No. E–
176–1999/0–US–01]; PCT Application
PCT/US01/00981, filed January 12, 2001
and currently expired [HHS Ref. No. E–
176–1999/0–PCT–02]; U.S. Patent
Application No. 10/169,975, filed July
12, 2002 and issued as U.S. Patent No.
7,087,589 on August 8, 2006 [HHS Ref.
No. E–176–1999/0–US–06]; U.S. Patent
Application No. 11/500,860, filed
August 8, 2006 and issued as U.S.
Patent No. 7,790,735 on September 14,
2006 [HHS Ref. No. E–176–1999/0–US–
07]; Australian Patent Application No.
2001230913, filed January 12, 2001 and
issued as Australian Patent No.
2001230913 on October 13, 2005 [HHS
Ref. No. E–176–1999/0–AU–03];
Canadian Patent Application No.
2,397,366, filed January 12, 2001 and
issued as Canadian Patent No. 2,397,366
on March 15, 2011 [HHS Ref. No. E–
176–1999/0–CA–04]; European Patent
Application No. 01903043.6, filed
January 12, 2001 and issued as
European Patent No. 1252160 on August
6, 2006 and currently abandoned [HHS
Ref. No. E–176–1999/0–EP–05]; and UK
Patent Application No. 01903043.6,
filed January 12, 2001 and issued as UK
Patent No. 1252160 on August 16, 2006
[HHS Ref. No. E–176–1999/0–GB–08],
entitled ‘‘Methanocarba Cycloalkyl
SUMMARY:
E:\FR\FM\27DEN1.SGM
27DEN1
sroberts on DSK5SPTVN1PROD with NOTICES
80956
Federal Register / Vol. 76, No. 248 / Tuesday, December 27, 2011 / Notices
Nucleoside Analogues’’ to Cornovus
Pharmaceuticals, Inc., a company
incorporated under the laws of the State
of Delaware having its headquarters in
Farmington, Connecticut. The United
States of America is the assignee of the
rights of the above inventions. The
prospective exclusive evaluation option
license territory may be ‘‘worldwide’’,
and the field of use may be limited to
‘‘The use of (1′S,2R,3S,4′R,5′S)-4-(6amino-2-chloro-9H-purin-9-yl)-1[phosphoryloxymethyl]
bicycle[3.1.0]hexane-2,3-diol)
(MRS2339) to treat and/or prevent
cardiac diseases in humans.’’ Upon the
expiration or termination of the
exclusive evaluation option license,
Cornovus Pharmaceuticals, Inc. will
have the right to execute an exclusive
patent commercialization license which
will supersede and replace the exclusive
evaluation option license with no
greater field of use and territory than
granted in the evaluation license.
DATES: Only written comments and/or
applications for a license received by
the NIH Office of Technology Transfer
on or before January 11, 2012 will be
considered.
ADDRESSES: Requests for a copy of the
patent application, inquiries, comments
and other materials relating to the
contemplated license should be directed
to: Suryanarayana (Sury) Vepa, Ph.D.,
J.D., Office of Technology Transfer,
National Institutes of Health, 6011
Executive Boulevard, Suite 325,
Rockville, MD 20852–3804; Telephone:
(301) 435–5020; Facsimile: (301) 402–
0220; Email: vepas@mail.nih.gov. A
signed confidentiality nondisclosure
agreement will be required to receive
copies of any patent applications that
have not been published or issued by
the United States Patent and Trademark
Office or the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION: The
present technology is premised upon
the novel combination of adenine and
uracil and their derivatives with a
constrained cycloalkyl group, typically
a cyclopentyl group. The constraint on
the cycloalkyl group is introduced by
fusion to a second cycloalkyl group. In
the case of cyclopentane, the fusion is
typically with cyclopropane. The
compounds disclosed in this technology
retain a surprising binding affinity
despite the substitution for the ribose
group. Moreover, the absence of the
glycosidic bond in the compounds
assists in improving the chemical
stability of these compounds and aids in
overcoming the stability problem
associated with the glycosidic bond in
previously known P1 and P2 receptor
VerDate Mar<15>2010
22:00 Dec 23, 2011
Jkt 226001
ligands. The compounds of the present
technology are useful in the treatment or
prevention of various cardiac and other
disorders.
The prospective exclusive evaluation
option license will comply with the
terms and conditions of 35 U.S.C. 209
and 37 CFR 404.7. The prospective
exclusive evaluation option license may
be granted unless, within fifteen (15)
days from the date of this published
notice, NIH receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications
for a license filed in response to this
notice will be treated as objections to
the contemplated license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection, and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: December 20, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2011–33131 Filed 12–23–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Coast Guard
[USCG–2011–1061]
Information Collection Request to
Office of Management and Budget;
OMB Control Number: 1625–0011
Coast Guard, DHS.
Sixty-day notice requesting
comments.
AGENCY:
ACTION:
In compliance with the
Paperwork Reduction Act of 1995, the
U.S. Coast Guard intends to submit an
Information Collection Request (ICR) to
the Office of Management and Budget
(OMB), Office of Information and
Regulatory Affairs (OIRA), requesting an
extension of its approval for the
following collection of information:
1625–0011, Applications for Private
Aids to Navigation and for Class I
Private Aids to Navigation on Artificial
Islands and Fixed Structures. Our ICR
describes the information we seek to
collect from the public. Before
submitting this ICR to OIRA, the Coast
Guard is inviting comments as
described below.
SUMMARY:
PO 00000
Frm 00089
Fmt 4703
Sfmt 4703
Comments must reach the Coast
Guard on or before February 27, 2012.
ADDRESSES: You may submit comments
identified by Coast Guard docket
number [USCG–2011–1061] to the
Docket Management Facility (DMF) at
the U.S. Department of Transportation
(DOT). To avoid duplicate submissions,
please use only one of the following
means:
(1) Online: https://www.regulations.
gov.
(2) Mail: DMF (M–30), DOT, West
Building Ground Floor, Room W12–140,
1200 New Jersey Avenue SE.,
Washington, DC 20590–0001.
(3) Hand delivery: Same as mail
address above, between 9 a.m. and 5
p.m., Monday through Friday, except
Federal holidays. The telephone number
is (202) 366–9329.
(4) Fax: (202) 493–2251. To ensure
your comments are received in a timely
manner, mark the fax, to attention Desk
Officer for the Coast Guard.
The DMF maintains the public docket
for this Notice. Comments and material
received from the public, as well as
documents mentioned in this Notice as
being available in the docket, will
become part of the docket and will be
available for inspection or copying at
room W12–140 on the West Building
Ground Floor, 1200 New Jersey Avenue
SE., Washington, DC, between 9 a.m.
and 5 p.m., Monday through Friday,
except Federal holidays. You may also
find the docket on the Internet at https://
www.regulations.gov.
A copy of the ICR is available through
the docket on the Internet at
https://www.regulations.gov.
Additionally, copies are available from:
COMMANDANT (CG–611), Attn:
Paperwork Reduction Act Manager, US
Coast Guard, 2100 2nd Street SW., Stop
7101, Washington, DC 20593–7101.
FOR FURTHER INFORMATION CONTACT:
Contact Ms. Kenlinishia Tyler, Office of
Information Management, telephone
(202) 475–3652, or fax (202) 475–3929,
for questions on these documents.
Contact Ms. Renee V. Wright, Program
Manager, Docket Operations, (202) 366–
9826, for questions on the docket.
SUPPLEMENTARY INFORMATION:
DATES:
Public Participation and Request for
Comments
This Notice relies on the authority of
the Paperwork Reduction Act of 1995;
44 U.S.C. Chapter 35, as amended. An
ICR is an application to OIRA seeking
the approval, extension, or renewal of a
Coast Guard collection of information
(Collection). The ICR contains
information describing the Collection’s
purpose, the Collection’s likely burden
E:\FR\FM\27DEN1.SGM
27DEN1
]]>Agencies
[Federal Register Volume 76, Number 248 (Tuesday, December 27, 2011)]
[Notices]
[Pages 80955-80956]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-33131]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License: Use of Methanocarba
Analogues of Purine and Pyrimidine Nucleosides and Nucleotides to Treat
or Prevent Cardiac Diseases in Humans
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37
CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH),
Department of Health and Human Services (HHS), is contemplating the
grant of a worldwide exclusive evaluation option license, to practice
the inventions embodied in U.S. Provisional Patent Application No. 60/
176,373, filed January 14, 2000 and currently abandoned [HHS Ref. No.
E-176-1999/0-US-01]; PCT Application PCT/US01/00981, filed January 12,
2001 and currently expired [HHS Ref. No. E-176-1999/0-PCT-02]; U.S.
Patent Application No. 10/169,975, filed July 12, 2002 and issued as
U.S. Patent No. 7,087,589 on August 8, 2006 [HHS Ref. No. E-176-1999/0-
US-06]; U.S. Patent Application No. 11/500,860, filed August 8, 2006
and issued as U.S. Patent No. 7,790,735 on September 14, 2006 [HHS Ref.
No. E-176-1999/0-US-07]; Australian Patent Application No. 2001230913,
filed January 12, 2001 and issued as Australian Patent No. 2001230913
on October 13, 2005 [HHS Ref. No. E-176-1999/0-AU-03]; Canadian Patent
Application No. 2,397,366, filed January 12, 2001 and issued as
Canadian Patent No. 2,397,366 on March 15, 2011 [HHS Ref. No. E-176-
1999/0-CA-04]; European Patent Application No. 01903043.6, filed
January 12, 2001 and issued as European Patent No. 1252160 on August 6,
2006 and currently abandoned [HHS Ref. No. E-176-1999/0-EP-05]; and UK
Patent Application No. 01903043.6, filed January 12, 2001 and issued as
UK Patent No. 1252160 on August 16, 2006 [HHS Ref. No. E-176-1999/0-GB-
08], entitled ``Methanocarba Cycloalkyl
[[Page 80956]]
Nucleoside Analogues'' to Cornovus Pharmaceuticals, Inc., a company
incorporated under the laws of the State of Delaware having its
headquarters in Farmington, Connecticut. The United States of America
is the assignee of the rights of the above inventions. The prospective
exclusive evaluation option license territory may be ``worldwide'', and
the field of use may be limited to ``The use of (1'S,2R,3S,4'R,5'S)-4-
(6-amino-2-chloro-9H-purin-9-yl)-1-[phosphoryloxymethyl]
bicycle[3.1.0]hexane-2,3-diol) (MRS2339) to treat and/or prevent
cardiac diseases in humans.'' Upon the expiration or termination of the
exclusive evaluation option license, Cornovus Pharmaceuticals, Inc.
will have the right to execute an exclusive patent commercialization
license which will supersede and replace the exclusive evaluation
option license with no greater field of use and territory than granted
in the evaluation license.
DATES: Only written comments and/or applications for a license received
by the NIH Office of Technology Transfer on or before January 11, 2012
will be considered.
ADDRESSES: Requests for a copy of the patent application, inquiries,
comments and other materials relating to the contemplated license
should be directed to: Suryanarayana (Sury) Vepa, Ph.D., J.D., Office
of Technology Transfer, National Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville, MD 20852-3804; Telephone: (301) 435-
5020; Facsimile: (301) 402-0220; Email: vepas@mail.nih.gov. A signed
confidentiality nondisclosure agreement will be required to receive
copies of any patent applications that have not been published or
issued by the United States Patent and Trademark Office or the World
Intellectual Property Organization.
SUPPLEMENTARY INFORMATION: The present technology is premised upon the
novel combination of adenine and uracil and their derivatives with a
constrained cycloalkyl group, typically a cyclopentyl group. The
constraint on the cycloalkyl group is introduced by fusion to a second
cycloalkyl group. In the case of cyclopentane, the fusion is typically
with cyclopropane. The compounds disclosed in this technology retain a
surprising binding affinity despite the substitution for the ribose
group. Moreover, the absence of the glycosidic bond in the compounds
assists in improving the chemical stability of these compounds and aids
in overcoming the stability problem associated with the glycosidic bond
in previously known P1 and P2 receptor ligands. The compounds of the
present technology are useful in the treatment or prevention of various
cardiac and other disorders.
The prospective exclusive evaluation option license will comply
with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The
prospective exclusive evaluation option license may be granted unless,
within fifteen (15) days from the date of this published notice, NIH
receives written evidence and argument that establishes that the grant
of the license would not be consistent with the requirements of 35
U.S.C. 209 and 37 CFR 404.7.
Properly filed competing applications for a license filed in
response to this notice will be treated as objections to the
contemplated license. Comments and objections submitted in response to
this notice will not be made available for public inspection, and, to
the extent permitted by law, will not be released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: December 20, 2011.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 2011-33131 Filed 12-23-11; 8:45 am]
BILLING CODE 4140-01-P
